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Edited by Robert BaroukiAbstract Nitric oxide (NO) is generated in endothelial cells,
which diﬀuses to vascular smooth muscle cells (SMCs), activates
soluble guanylyl cyclase, and leads to blood vessel dilation. How-
ever, this scenario does not explain how SMCs are capable of
competing with erythrocytic hemoglobin for NO in vivo. Here,
we have developed a competition experiment to determine the
NO uptake rate by SMCs and demonstrated that the SMC-
NO uptake rate is positively dependent on intracellular superox-
ide levels. In addition, the superoxide-elicited NO inﬂux is able
to enhance cGMP production in SMCs. Our ﬁndings imply that
vascular SMCs, in vivo, may use superoxide to compete with
erythrocytic hemoglobin for NO and obtain the NO bioactivity.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Nitric oxide (NO) involves in a variety of physiological func-
tions, including dilation of blood vessels, induction of innate
immune response, and neural communication in brain [1,2].
In vasculature, the high reactivity of NO with hemoglobin
(Hb) in blood [3,4] (kHb = 5 · 107 M1 s1) makes it diﬃcult
to exert its vasoactivity without a mechanism either to reduce
the NO consumption rate by red blood cells or to increase the
transfer rate of NO into smooth muscle cells (SMCs). In red
blood cells, the membrane associated with the NO-inert pro-
teins [5], Band 3 [6], deoxyhemoglobin (deoxyHb) [7], and
nitrosyl hemoglobin [8] can modulate the NO bioavailability.
However, the mechanism of NO transport into SMCs remains
unknown, except that it is generally believed to be passive dif-
fusion. In particular, whether the NO uptake by SMCs is mod-
ulated is still unclear.
One factor thatmightmodulateNOuptake by SMCs is super-
oxide, which in vascular SMCs is produced mainly from the
membrane-bound NAD(P)H oxidase [9]. Superoxide reacts
with NO at an extremely high rate [10] ðkO
2
 1.6
1010 M1 s1Þ, resulting in the production of peroxynitrite.Abbreviations: NO, nitric oxide; SMC, smooth muscle cells; Hb,
hemoglobin; SpNO, spermine NONOate; Ang II, angiotensin II; IP3,
Inositol-1,4,5-triphosphate; SOD, superoxide dismutase
*Corresponding author. Fax: +886 5 272 1206.
E-mail address: chmkth@ccu.edu.tw (K.-T. Huang).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2005.06.071Although less potent than NO, peroxynitrite via generation of
NO donors has been reported to induce vasodilatation in the
perfused rat heart [11] and relaxation in isolated vessels
[12,13]. Its high reactivity with NO and ability to generate NO
donors make superoxide in SMCs a possible role in competing
with erythrocyticHb forNOandmodulating theNObioactivity
in vivo.
In this study, we hypothesize that SMCs may use superoxide
to gain the NO bioactivity through competition with erythro-
cytic Hb for NO. To test whether superoxide modulates NO
uptake rate in SMCs, we developed an innovative method
based on competition between SMCs and Hb to determine
the SMC-NO uptake rate [5,14,15]. Our results show that
superoxide determines the NO uptake rate and increases intra-
cellular cGMP production in SMCs while competing with
extracellular Hb for NO.2. Materials and methods
2.1. Cell culture
Rat SMCs A7r5 (ATCC CRL-1444) were maintained in Dulbeccos
modiﬁed Eagles medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS). Human aortic SMCs (Cascade Biologics) were cul-
tured in DMEM/F-12 1:1 mixture containing smooth muscle growth
supplement (Cascade Biologics) and 10% FBS. To determine the eﬀect
of cell conﬂuence, the rat SMCs were passed onto 24-well cell culture
dishes at 40% and 100% of cell conﬂuence upon reaching conﬂuence
and the measurements were taken 24 h after passage. To determine
the serum eﬀect, the percentage of FBS in the medium was reduced
to 4% after cells reaching conﬂuence. Thereafter, cells were cultured
for one more day and then passed onto 24-well cell culture dishes at
30% of cell conﬂuence. One day after passage, the percentages of
FBS in the media were further adjusted to 10% and 0.3%, respectively.
The investigations were performed 24 h after the last adjustment of ser-
um concentration. For treatment of human SMCs with angiotensin II
(Ang II), the concentrations of Ang II and FBS were 0.1 lM and 0.1%,
respectively. The level of cell conﬂuence was about 60%.2.2. Preparation of oxyHb solution
The human blood was collected in heparinized (10 unit/mL) tubes
and centrifuged at 800 · g for 10 min. The puriﬁcation of oxyHb
was performed as described earlier [15].2.3. The competition experiment
We have previously succeeded in measuring the NO uptake rate by
red blood cells using a competition experiment [14,15]. This concept of
competition can also be applied to measure the NO uptake by SMCs.
However, diﬀerent from red blood cells, SMCs attach to the culture
dish and do not have a high concentration of heme proteins to
inﬂuence the Hb absorbance. Therefore, we can culture SMCs in a
multi-well dish, have them compete with oxyHb for NO, and directly
measure the metHb production in the solution using a plate readeration of European Biochemical Societies.
Fig. 1. Determination of NO uptake rate by SMCs using a compe-
tition experiment. (A) During the time course, the soret peak of Hb
shifts from 415 to 408 nm in 90 min due to the oxyHb-NO reaction in
the cell-free sample. (B) The shift of Hb soret peak is less under the
competition of rat SMCs for NO as compared with the cell-free
sample. Arrows denote direction of the increase of time. (C) The
metHb production is less in the presence (ﬁlled circle) than in the
absence (open circle) of rat SMCs. (D) The SMC-NO uptake rate
constant, kSMC½O2 =kHb, determined from the slope of the plot is equal
to (2.4 ± 0.2) · 104 lM. All data represent means ± S.E. for n = 6.
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of experiments consisted of four samples in a 24-well cell culture dish,
ran simultaneously, which contained Hb only, Hb with spermine
NONOate (SpNO), SMCs and Hb, and SMCs and Hb with SpNO,
respectively. The solutions that do not contain the NO donor ensured
that the Hb autooxidation and the SMC-mediated Hb oxidation and
reduction were taken into account. One molecule of SpNO can releases
two molecules of NO [16]. The working medium was 250 lL of phenol
red-free DMEM and DMEM/F-12 containing 16-lM oxyHb (based
on heme). For the samples with NO donor, 12 lM of SpNO was added
immediately after dissolving in HEPES buﬀer. All solutions were
gently shaken and maintained at 37 C and the absorbance spectra
from 380 to 460 nm were taken at the indicated time intervals. The
method of Moore-Penrose pseudo-inverse was used to determine the
oxyHb and metHb concentration in the solution [17].
2.4. Kinetic modeling and data interpretation of competition experiments
The ratio of NO consumption rates between oxyHb and SMCs in
the SMC-containing sample is determined by comparing the metHb
production rate with the NO production rate from the donor. We as-
sume that the NO concentration in the solution is homogeneous, thus
the pseudo-steady-state equation for NO in solution can be written as
2kd½spNO  kHb½oxyHb½NO  rvkSMC½O2 ½NO ¼ 0. ð1Þ
Here kd is the rate constant for NO release and [spNO] is the donor
concentration. kHb is the rate constant for the oxyHb-NO reaction
and [oxyHb] and [NO] are the oxyHb and NO concentrations in bulk
medium, respectively. The SMC-NO reaction rate is expressed as
kSMC½O2 [NO] and rv is the volumetric ratio of SMCs to solution. kSMC
is the rate constant for the SMC-NO reaction and ½O2  is the intracel-
lular superoxide concentration. The NO release rate from the donor
and the oxyHb-NO reaction rate in the cell-containing sample can
be determined from the rate of metHb productions in the cell-free
and -containing samples, respectively:
2kd½spNO ¼ d½metHbcf
dt
ð2Þ
and
kHb½oxyHb½NO ¼ d½metHb
dt
ð3Þ
where [metHb] and [metHb]cf are the metHb concentrations in the
samples with and without SMCs, respectively. Combining Eqs. (1)–
(3) and integrating the resulting equation gives
½metHbcf  ½metHb ¼
kSMC
kHb
rv½O2  ln
½oxyHb0
½oxyHb
 
ð4Þ
where [oxyHb]0 is the initial concentration of oxyHb in the medium.
kSMC½O2 =kHb can be determined from the slope of the plot of Eq.
(4) and is an indicator for the SMC-NO uptake rate.
2.5. Detection of superoxide
The intracellular concentration of superoxide was evaluated using
the oxidative ﬂuorescent dye hydroethidine [18] (Sigma) by ﬂuores-
cence-activated cell sorting (FACS). After treatments, SMCs were
washed three times with Dulbeccos phosphate-buﬀered saline (DPBS),
incubated with 3-lM hydroethidine in DPBS at 37 C for 30 min, and
washed three times with DPBS. The cells after the dye loading were
mobilized with 0.25% trypsin and 0.02% EDTA. Thereafter, SMCs
were harvested, centrifuged, and washed three times with DPBS.
FACS was run with a FACScalibur (Becton–Dickinson company).
2.6. Measurement of intracellular cGMP
The SMCs ﬁrst were treated with phosphodiesterase inhibitor 0.2-
mM 3-isobutyl-1-methylxanthine 30 min before the competition exper-
iments. At the end of competition experiments, cells were lysed for
measuring the intracellular cGMP concentration using enzyme immu-
noassay (Assay Designs).
2.7. Data analysis
Results are given as means ± S.E. Data were analyzed with an un-
paired two-tailed t test. Diﬀerences were considered to be signiﬁcant
at P < 0.05.3. Results
3.1. Measurement of NO uptake rate in vascular SMCs
In the circulation, NO released from endothelium is in a
nanomolar range [19], which can dilate the blood vessels under
an 11-mM erythrocytic Hb concentration (based on heme).
Furthermore, NO consumption by red blood cells is about
500–1000 times slower than that by free oxyHb [15,20]. There-
fore, red blood cells that compete with vascular SMCs for NO
in vivo exhibit reactivity equivalent to about 15 lM of free
oxyHb. To mimic this physiological condition, we designed a
competition experiment in which rat vascular SMCs at 40%
conﬂuence and free oxyHb (15 lM) both compete for NO.
NO is generated from SpNO, an NO donor. The production
of metHb in solutions in a 24-well cell culture dish was moni-
tored directly using the microplate reader to attain spectra of
Hb solution every 20–30 min. The Soret peak of Hb shifts
from 415 to 408 nm at 90 min in the cell-free control
(Fig. 1A) and to 411 nm, also at 90 min, in the cell-containing
sample (Fig. 1B), suggesting the formation of metHb from
oxyHb, as expected. The corresponding metHb productions
in the cell-free and cell-containing samples at 90 min are
8.14 ± 0.64 and 4.06 ± 0.11 lM (means ± S.E., n = 6), respec-
tively (Fig. 1C). These results demonstrate that SMCs is capa-
ble of competing for NO in the presence of 15-lM free oxyHb.
To determine the SMC-NO uptake rate, we plotted the data
based on Eq. (4) derived in Section 2 and ﬁtted with a straight
line (Fig. 1D), indicating that the result is consistent with our
kinetic model. The slope represents kSMC½O2 =kHb and is equal
to (2.4 ± 0.2) · 104 lM (mean ± S.E., n = 6) as the volumetric
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Fig. 3. Reduction of the SMC-NO uptake rate by the superoxide
scavenger. One hour pre-treatment of the cells at 40% conﬂuence with
10 mM tiron reduces both the hydroethidine-emitted ﬂuorescence (A)
and the SMC-NO uptake rate (B). All data represent means ± S.E. for
n = 4–6. \P < 0.05 vs. control.
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based on a 1.5-lm thickness of the SMC [21].
3.2. Superoxide determination of the SMC-NO uptake rate
To identify whether intracellular superoxide in SMCs is the
major competitor to erythrocytic Hb for NO, we compared the
NO uptake rates by SMCs with various intracellular superox-
ide concentrations. The level of intracellular superoxide was
adjusted by varying serum concentrations or cell conﬂuence
and was detected using FACS with hydroethidine ﬂuorescence
dye. The mean ﬂuorescence intensities of SMCs are 24.5 ± 0.4
(means ± S.E., n = 3), 18.1 ± 0.2 (means ± S.E., n = 3),
42.6 ± 2.4 (means ± S.E., n = 3), and 56.6 ± 1.1 (means ± S.E.,
n = 3) for the cells at 40% and 100% cell conﬂuence and the
cells cultured in 0.3% and 10% serum concentrations, respec-
tively (Fig. 2A and B). The SMC-NO uptake rate is positively
dependent on the level of intracellular superoxide and is inde-
pendent on the type of treatment (Fig. 2C). Pre-treatment of
SMCs at 40% cell conﬂuence with a superoxide scavenger (tir-
on, 10 mM) reduces the intracellular superoxide concentration
and the SMC-NO uptake rate (Fig. 3). These results demon-
strate that the cells with higher intracellular superoxide con-
centration will exhibit a greater SMC-NO uptake rate in the
competition experiment.
To investigate whether the same mechanism of the SMC-NO
uptake also exists in human SMCs, we determined the NO up-
take rate using human aortic SMCs exposed to Ang II, the ac-
tive component of the renin–angiotensin system, to alter their
intracellular superoxide concentrations [9,22]. The level of
intracellular superoxide is increased at 0.5 h after the onset
of Ang II challenge, but the eﬀect diminishes after 4 h of treat-
ment (Fig. 4A). The trend of the SMC-NO uptake rate is sim-
ilar to that of intracellular superoxide concentration (Fig. 4A
and B). Furthermore, pre-treatment of cells with tiron
(10 mM) is capable of attenuating the level of intracellular
superoxide and SMC-NO uptake rate at 0.5 h after Ang II
challenging (Fig. 4A and B). These results suggest that super-
oxide aﬀects NO uptake rates in both human and rat SMCs.
3.3. Enhancement of the NO-cGMP signaling by superoxide in
SMCs in the competition experiment
To test whether the superoxide-enhanced NO uptake rate in
the competition experiment is able to increase the intracellular-
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level of mean hydroethidine-emitted ﬂuorescence intensity in rat SMCs.cGMP production, we pretreated rat SMCs at 40% conﬂuence
with tiron (10 mM), conducted the competition experiment as
described earlier, and then compared their intracellular cGMP
production. The cGMP production is higher in the presence of
spNO (Fig. 5). Pre-treatment of cells with tiron (10 mM) sig-
niﬁcantly attenuates the basal and NO-stimulated cGMP pro-
duction at 12 min (Fig. 5), demonstrating that when the level
of intracellular sGC remains constant, the higher concentra-
tion of intracellular superoxide, the greater the intracellular
cGMP production.4. Discussion
The lack of an experimental design to determine the NO up-
take rate by SMCs has prevented resolving the mechanism of
NO transport into SMCs. In the present study, we successfully
determined the SMC-NO uptake rate by a new method based
on competition between SMCs and Hb for NO and further
demonstrated that the NO uptake rate can be modulated by
superoxide in SMCs. These results not only provide a possible
mechanism for NO transport into SMCs but also imply that
the superoxide-elicited NO uptake in SMCs might also in-
crease the NO bioactivity to gain its physiological signiﬁcance.0
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Fig. 5. Superoxide modulation of the NO-cGMP signaling. The NO
donor, spNO, enhances the intracellular cGMP production in rat
SMCs. Pre-treatment with 10 mM tiron decreases the basal and NO-
stimulated cGMP production in the presence of extracellular oxyHb.
All data represent means ± S.E. for n = 4. \P < 0.05 vs. Hb/spNO;
\\P < 0.05 vs. Hb alone.
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enhance the NO-mediated cGMP production in the presence
of oxyHb completing for NO.
It could be argued that the superoxide-elicited NO uptake
rate by SMCs in the competition experiments is an artifact
due to reduction of extracellular metHb by the export of super-
oxide from SMCs. However, when we incubated SMCs with
metHb for the same duration as the competition experiment,
there was only negligible amount of metHb reduced. There-
fore, reduction of metHb by exported superoxide would not
aﬀect our results signiﬁcantly. Furthermore, although the Hb
concentration is about ﬁve orders of magnitude greater than
the steady-state NO concentration (about 30 pM derived from
the metHb production rate in the cell-free sample) in the com-
petition experiment, the rate constant of the superoxide-
metHb reaction [23] is about seven orders of magnitude lessthan that of the superoxide-NO reaction. Therefore, the export
of superoxide from SMCs reacts mainly with NO to produce
peroxynitrite and in turn causes oxidation of oxyHb [24,25],
but not reduction of metHb. This oxidation of extracellular
oxyHb by peroxynitrite would result in an apparently lower
NO uptake rate by SMCs.
The pronounced superoxide dependence of NO uptake rate
(Fig. 2C) reveals that the majority of NO transported into
SMCs may react with superoxide to form peroxynitrite. Perox-
ynitrite has been shown to produce NO-like molecules through
S-nitrosation to induce relaxation of vascular smooth muscle
[13,26,27]. However, the potency of peroxynitrite to produce
cGMP is about three orders of magnitude less than that of free
NO [25]. Therefore, the production of cGMP in SMCs is more
sensitive to free NO than peroxynitrite. Notably, free NO
could be preserved and generated by CuZn-superoxide dismu-
tase (CuZn-SOD) via limitation of the superoxide availability
and decomposition of S-nitrosothiols, respectively [28–33].
The ability of CuZn-SOD to remove superoxide can be mim-
icked by tiron. Treatment of SMCs with tiron decreases both
NO inﬂux and cGMP production in the competition experi-
ment (Figs. 3 and 5), implying that the beneﬁcial eﬀect of the
expression of CuZn-SOD in SMCs on vessel responses could
be due to degradation of S-nitrosothiols other than simple
superoxide scavenging.
Overlooking competition between superoxide and erythro-
cytic Hb for NO in vivo has produced some paradoxical ﬁnd-
ings [28]. For instance, the isolated carotid arteries from
CuZn-SOD-deﬁcent mice has shown a greater superoxide
production and resulted in the impairment of endothelium-
dependent vessel dilation. However, the CuZn-SOD-deﬁcient
mice develops lower blood pressure as compared to their
wild-type littermates [28]. The eﬀects of CuZn-SOD on the
vascular function are complex and are dependent on its loca-
tions. The deﬁcient CuZn-SOD activity increases the intracel-
lular superoxide levels and results in the decrease of NO
release from endothelial cells [31,32], which may be in favor
of blood vessel constriction. However, the increase of NO in-
ﬂux by superoxide in SMCs likely, at least in part, help to
conquer the above contraction eﬀects and lead to low blood
pressure in the CuZn-SOD-deﬁcient mice.
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through the increase of NO uptake rate might provide an addi-
tional control circuitry for the signaling mediated by Ang II or
other signaling molecules (Fig. 4). Ang II has been reported to
increase intracellular free calcium via inﬂux of extracelluar cal-
cium and inositol-1,4,5-triphosphate (IP3)-sensitive calcium
stores [34]. Ang II, however, also increases superoxide produc-
tion via membrane-associated NAD(P)H oxidase [22,35].
Therefore, increased superoxide production might attenuate
the Ang II-stimulated calcium response via the promotion of
the NO-cGMP signaling pathways that activate the cGMP-
dependent protein kinases and inhibit the accumulation of
IP3 [36].
In conclusion, the mechanism of NO transport into SMCs is
of physiological importance as it determines the blood vessel
response to the endothelial derived NO. Our new assay with
its ability to measure the SMC-NO uptake rate at physiologi-
cally meaningful conditions has provided us with a tool to
identify superoxide in SMCs as a determinant for the NO up-
take rate. Furthermore, the discovery of superoxide in SMCs
modulating positively the NO bioactivity may help gain better
insight into the development of therapeutic strategies for vas-
cular diseases.
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